Mayne Pharma operates as a hybrid specialty pharmaceutical enterprise rather than a pure generic manufacturer, combining a growing portfolio of proprietary branded therapeutics with an established generic drug division. While the company historically built substantial capabilities in generic pharmaceuticals and advanced oral drug delivery systems, its contemporary strategic direction heavily emphasizes high-margin specialty branded products, particularly within targeted therapeutic categories like dermatology and women's health. This dual focus allows the company to capture stable baseline revenues from generics while pursuing higher-margin growth through specialized branded innovations.